{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:54:46Z","timestamp":1767149686717,"version":"build-2238731810"},"reference-count":48,"publisher":"Elsevier BV","issue":"9456","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/s0140-6736(05)17790-3","type":"journal-article","created":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T13:14:04Z","timestamp":1106658844000},"page":"341-346","source":"Crossref","is-referenced-by-count":142,"title":["Can meta-analysis help target interventions at individuals most likely to benefit?"],"prefix":"10.1016","volume":"365","author":[{"given":"Simon G","family":"Thompson","sequence":"first","affiliation":[]},{"given":"Julian PT","family":"Higgins","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(05)17790-3_bib1","series-title":"Systematic reviews in health care: meta-analysis in context","author":"Egger","year":"2001"},{"key":"10.1016\/S0140-6736(05)17790-3_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/sim.4780060312","article-title":"Problems in the medical interpretation of overviews","volume":"6","author":"Wittes","year":"1987","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.309.6954.597","article-title":"Rationale for systematic reviews","volume":"309","author":"Mulrow","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(05)17790-3_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/sim.4780060306","article-title":"Why do we need systematic overviews of randomised trials?","volume":"6","author":"Peto","year":"1987","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198604033141406","article-title":"Determining optimal therapy: randomized trials in individual patients","volume":"314","author":"Guyatt","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib6","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/S0140-6736(95)90120-5","article-title":"Can overall results of clinical trials be applied to all patients?","volume":"345","author":"Rothwell","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)17790-3_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-116-1-78","article-title":"A consumers' guide to subgroup analyses","volume":"116","author":"Oxman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/bmj.309.6965.1351","article-title":"Why sources of heterogeneity in meta-analysis should be investigated","volume":"309","author":"Thompson","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(05)17790-3_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/oxfordjournals.aje.a117645","article-title":"Benefits of heterogeneity in meta-analysis of data from epidemiologic studies","volume":"142","author":"Berlin","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/S0140-6736(05)17790-3_bib10","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/bmj.315.7122.1610","article-title":"Meta-analysis: beyond the grand mean?","volume":"315","author":"Davey Smith","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(05)17790-3_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(97)08468-7","article-title":"Summing up evidence: one answer is not always enough","volume":"351","author":"Lau","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)17790-3_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4300","article-title":"A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb\/IIIa antagonists in the medical management of unstable angina","volume":"4","author":"McDonagh","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1016\/S0140-6736(05)17790-3_bib13","series-title":"Guidance on the use of glycoprotein IIb\/IIIa inhibitors in the treatment of acute coronary syndromes (NICE Technology Appraisal Guidance No 12)","year":"2000"},{"key":"10.1016\/S0140-6736(05)17790-3_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002130","article-title":"Platelet glycoprotein IIb\/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction (Cochrane Review)","volume":"4","author":"Bosch","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S0140-6736(05)17790-3_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)17790-3_bib16","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib17","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","author":"The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib18","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","article-title":"International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina","volume":"97","author":"The PARAGON Investigators","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(05)17790-3_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"The PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib20","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial","volume":"357","author":"GUSTO IV-ACS Investigators","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)17790-3_bib21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/hc0302.102573","article-title":"The platelet IIb\/IIIa antagonist for the reduction of acute coronary syndrome events. Randomized, placebo-controlled trials of titrated intravenous lamifiban and acute coronary syndromes","volume":"105","author":"Global Organization Network (PARAGON-B) Investigators","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(05)17790-3_bib22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D","article-title":"Detecting and describing heterogeneity in meta-analysis","volume":"17","author":"Hardy","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib23","first-page":"164","article-title":"Down with odds ratios!","volume":"1","author":"Sackett","year":"1996","journal-title":"Evidence-based Medicine"},{"key":"10.1016\/S0140-6736(05)17790-3_bib24","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"Deeks","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0197-2456(94)90024-8","article-title":"Generalizing the results of randomized clinical trials","volume":"15","author":"Bailey","year":"1994","journal-title":"Control Clin Trials"},{"key":"10.1016\/S0140-6736(05)17790-3_bib26","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.318.7197.1548","article-title":"Numbers needed to treat derived from meta-analyses: sometimes informative, usually misleading","volume":"318","author":"Smeeth","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(05)17790-3_bib27","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/bmj.311.7016.1356","article-title":"An evidence based approach to individualizing treatment","volume":"311","author":"Glasziou","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(05)17790-3_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/sim.4780140406","article-title":"A random-effects regression model for meta-analysis","volume":"14","author":"Berkey","year":"1995","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib29","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V","article-title":"Explaining heterogeneity in meta-analysis: a comparison of methods","volume":"18","author":"Thompson","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib30","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib31","first-page":"16","article-title":"Meta-analysis regression","volume":"42","author":"Sharp","year":"1998","journal-title":"Stata Technical Bulletin"},{"key":"10.1016\/S0140-6736(05)17790-3_bib32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/bmj.313.7059.735","article-title":"The relation between treatment benefit and underlying risk in meta-analysis","volume":"313","author":"Sharp","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(05)17790-3_bib33","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/1097-0258(20001215)19:23<3251::AID-SIM625>3.0.CO;2-2","article-title":"Analysing the relationship between treatment benefit and underlying risk in meta-analysis: comparison and development of approaches","volume":"19","author":"Sharp","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib34","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/sim.1184","article-title":"Statistical methods for assessing the influence of study characteristics on treatment effects in \u2018meta-epidemiological\u2019 research","volume":"21","author":"Sterne","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0895-4356(01)00414-0","article-title":"A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis","volume":"55","author":"Lambert","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/S0140-6736(05)17790-3_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1258\/1355819021927674","article-title":"Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice","volume":"7","author":"Higgins","year":"2002","journal-title":"J Health Serv Res Policy"},{"key":"10.1016\/S0140-6736(05)17790-3_bib37","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)17790-3_bib38","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/sim.4780141902","article-title":"Practical methodology of meta-analyses (overviews) using updated individual patient data","volume":"14","author":"Stewart","year":"1995","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib39","series-title":"Practical statistics for medical research","author":"Altman","year":"1991"},{"key":"10.1016\/S0140-6736(05)17790-3_bib40","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/0895-4356(93)90120-P","article-title":"The design of prospective epidemiological studies: more subjects or better measurements?","volume":"46","author":"Phillips","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/S0140-6736(05)17790-3_bib41","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/sim.918","article-title":"Meta-analysis of continuous outcome data from individual patients","volume":"20","author":"Higgins","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(05)17790-3_bib42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1191\/096228001682157616","article-title":"Multilevel models for meta-analysis, and their application to absolute risk differences","volume":"10","author":"Thompson","year":"2001","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/S0140-6736(05)17790-3_bib43","author":"National Institute for Clinical Excellence"},{"key":"10.1016\/S0140-6736(05)17790-3_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(05)17790-3_bib45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(94)91161-4","article-title":"Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)17790-3_bib46","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(98)11415-0","article-title":"Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study","volume":"353","author":"Rothwell","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)17790-3_bib47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(94)91963-1","article-title":"Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration","volume":"344","author":"Yusuf","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)17790-3_bib48","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(94)92407-4","article-title":"Completeness of reporting trial results: effect on physicians' willingness to prescribe","volume":"343","author":"Bobbio","year":"1994","journal-title":"Lancet"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0140673605177903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0140673605177903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T04:18:54Z","timestamp":1625372334000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673605177903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":48,"aliases":["10.1016\/s0140-6736(05)70200-2"],"journal-issue":{"issue":"9456","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0140673605177903"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(05)17790-3","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}